In Vivo Evaluation of Antiviral Compounds on Respiratory Syncytial Virus Using a Juvenile Vervet Monkey (Chlorocebus pygerythrus) Infection Model
Several animal models with varying susceptibilities to respiratory syncytial virus (RSV) infection have been developed to study the specific aspects of RSV disease. Many of these models are used for testing antiviral compounds or in vaccine efficacy studies during preclinical evaluation. In this chapter, we describe the study design of an efficacy study of an RSV inhibitor, performed in a juvenile vervet monkey model for RSV.
Key wordsRespiratory syncytial virus Monkey model RSV inhibitor Animal infection model
This research was supported in part by a grant of the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT), project number 070005. Piet Maes is supported by a postdoctoral grant from the “Fonds voor Wetenschappelijk Onderzoek (FWO)-Vlaanderen”. We gratefully acknowledge Dr. Thomas Karuiki and the staff at the Institute of Primate Research, Nairobi, Kenya for the excellent technical assistance. We would also like to thank our colleagues of the Laboratory of Clinical Virology and R&D of Janssen Infectious Diseases for their contribution to the study design and review of the manuscript.
- 10.Houspie L, Ipsas G, Keyaerts E et al (2013) Juvenile vervet monkey model for human respiratory syncytial virus infection (manuscript in preparation)Google Scholar